People | November 11, 2022
Biogen appoints Christopher Viehbacher as President and CEO
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective January 1, 2023
The companies will continue with their exclusive agreements, including commercialization of their current portfolio
The BLA is being submitted under the accelerated approval pathway and is primarily based on clinical, biomarker and safety data from the Phase 2b clinical trial in people with early AD and confirmed amyloid pathology
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)